SNX13

Across TCGA pan-cancer cohorts, SNX13 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SNX13 data layer compared with 25 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SNX13 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated SNX13 expression acts as an unfavorable survival marker, although some lineages such as OV and CCRCC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where SNX13 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.294	0.536	.001	29	view →
HNSC	DFS	Quartile	All	0.266	1.000	.036	12	view →
LSCC	DFS	Tertile	II,III,IV	0.187	0.793	.004	10	view →
OV	DFS	Median	All	1.000	0.857	.042	4	view →
CCRCC	DFS	Quartile	All	0.899	0.663	.042	2	view →
GBM	DFS	Quartile	All	0.838	0.580	.043	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SNX13–PDAC (DFS)

Open the PDAC breakdown →